The gain came as the S&P 500 climbed 1.46% to 7,365.12 and the Dow added 1.24% to 49,910.59 in a broad market rally.
It was Incyte's fourth straight daily advance, though the shares still closed 11.08% below their 52-week high of $112.29 reached on 7 January.
Among peers, Alnylam rose 0.63%, BioMarin gained 2.55% and Bio-Techne fell 16.36%, while Incyte trading volume of 1.2 million stayed below its 50-day average of 1.6 million.
With Incyte's stock price rising, why are its top executives selling shares?
After a blockbuster quarter, why is Incyte's management lowering future expectations?
Can Incyte's promising new drugs overcome increasing scrutiny from the FDA?